Immersion

Does ketamine work better when antidepressants have failed?

Empty treatment chair with folded lavender blanket.

Last updated

Short answer

Often, yes. A 2022 analysis that pooled individual patient data from randomized ketamine trials found intravenous ketamine lowered depression scores more than placebo at about 24 hours, a moderate effect near 0.58. The benefit was larger in people whose depression had resisted more prior medications, not smaller.

The research
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., and colleagues (2022). International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Molecular Psychiatry, 2022.
Sample Pooled individual-patient data from multiple randomized controlled trials of intravenous ketamine
Published 2022
Journal Molecular Psychiatry
Rebecca Price and an international team did something most reviews cannot. Instead of pooling only the summary results of each trial, they pooled the individual patient data from randomized trials of intravenous ketamine for depression, which lets the analysis ask who responds, not just whether the drug works on average. Across that combined sample, ketamine lowered depression scores more than an inactive placebo at about 24 hours. The size of that edge was a standardized effect of around 0.58. A standardized effect is a way of comparing results that were measured on different scales, and 0.58 sits in the moderate range: a clear, real difference rather than a small one. The finding that stands out is about who gained the most. The benefit was larger, not smaller, in people whose depression had already failed to respond to more prior medications. The authors describe ketamine as robustly reducing symptoms across a mixed, real-world group of patients, while being careful to add that the work of pinning down exactly which patients respond best, what they call precision-medicine moderators, is not finished.
Read the paper

What does this mean for you?

Here is the plain version. On average, across these trials, people given ketamine improved more than people given a placebo, and the gap showed up fast, within about a day. Moderate is the right word for the size of it. That means real, and worth taking seriously, but not magic.

The surprising part is the direction. With a lot of treatments you might expect the hardest cases to gain the least. Here it was the reverse. The more antidepressants a person had already tried without relief, the clearer ketamine's edge over placebo. That is unusual, and it is a big part of why ketamine is studied for depression that has not budged on standard medication.

There are honest limits. This is an average across different trials and different people, so it does not promise anything for any one person. It measured the first day or so, not the months that follow, so it speaks to a rapid early lift far more than to how long that lift lasts. And the authors were clear that knowing in advance exactly who will benefit most is still unfinished work.

So the fair reading for the gap between sessions is this. Where ketamine is used, it tends to act like a jolt at the start, not the whole of the treatment. The days and weeks after, when a person is trying to hold on to an early lift and build something on it, are where that gain is kept or quietly lost.

The takeaway

Terms in this page

This is the work Asendar™ was built for: the stretch after a treatment, when a fast early lift has to be held onto and built into ordinary days. If you want a simple read on where your head is starting from today, take your Mental Readiness Score.

Start free: get your Mental Readiness Score

Your Mental Readiness Score is a short daily check-in on how steady you feel today. Free, web app, no download.

Explore more in the Immersion pillar